Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maidah Malik"'
Autor:
MAIDAH MALIK, HAFIZ MUHAMMAD SIDDIQUE QURASHI, IULIIA KOVALENKO, TABINDA SALEEM, KONSTANTIN GOLUBYKH, TAJ RAHMAN, SANTHOSH GHEEVARGHESE JOHN
Publikováno v:
Chest. 162:A605-A606
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbbb60958302c9da3b5ff2884afd4c61
https://doi.org/10.1016/j.chest.2022.08.473
https://doi.org/10.1016/j.chest.2022.08.473
Autor:
Iuliia Kovalenko, Konstantin Golubykh, Adan Martin Cuevas Velazquez, Nadim Ammari, Maidah Malik, Manpreet Sandhu, Hafiz Qurashi, Tabinda Saleem, Anas Atrash, Saketram Komanduri, Yijin Wert, Kit Lu
Publikováno v:
Journal of Clinical Oncology. 40:22-22
22 Background: The American Society of Hematology (ASH) Choosing Wisely campaign have created thoughtful conversations between providers and patients in recommending care that is supported by evidence to reduce duplicative testing. However, some have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beaa2348e87950b629470df5028a8b16
https://doi.org/10.1200/jco.2022.40.28_suppl.022
https://doi.org/10.1200/jco.2022.40.28_suppl.022
Publikováno v:
Chest. 162:A167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8312614bd35f8c370e224b7fc420c859
https://doi.org/10.1016/j.chest.2022.08.121
https://doi.org/10.1016/j.chest.2022.08.121
Autor:
IULIIA KOVALENKO, KONSTANTIN GOLUBYKH, RIMSHA ALI, TAAHA M MIRZA, MAIDAH MALIK, NAVITHA RAMESH
Publikováno v:
Chest. 162:A1432
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f1ca3b2c8b7ec5ac4847c22a40ee6a7
https://doi.org/10.1016/j.chest.2022.08.1204
https://doi.org/10.1016/j.chest.2022.08.1204
Autor:
Iuliia Kovalenko, Tabinda Saleem, Babray Laek, Rimsha Ali, Taaha Muddassir Mirza, Asmi Chattaraj, Ahsan Wahab, Asma Tamez ud din, Hafiz Qurashi, Konstantin Golubykh, Maidah Malik, Rafiullah Khan
Publikováno v:
Journal of Clinical Oncology. 40:e19053-e19053
e19053 Background: Ruxolitinib, an elective Janus Kinase (JAK) 1/2 inhibitor, has been approved by FDA for the treatment of steroid-refractory chronic graft-versus-host-disease (SR cGVHD) after the failure of one or two lines of systemic therapy in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14b0183651b350c39a7c8c737cd81f3c
https://doi.org/10.1200/jco.2022.40.16_suppl.e19053
https://doi.org/10.1200/jco.2022.40.16_suppl.e19053